OS Therapies - OSTX Operating profit EBITDA
OS Therapies Incorporated (OSTX) focuses on treating rare pediatric bone tumors by developing anti-metastatic vaccines. Operating profit in cash equivalents on the general GURU.Markets platform chart shows that the current parameter is 0.00. This is supported by scientific alliances with oncology centers to develop immunotherapy, while operational processes are optimized by outsourcing trials to contract research organizations (CRO).
Summary analytical data breakdowns for OS Therapies (OSTX)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Capital OS Therapies Incorporated|OSTX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient OS Therapies Inc.|OSTX - Company Total Debt|Debt to Net Assets Ratio OS Therapies|OSTX - Company Long-Term Liabilities|Amount of Current Liabilities OS Therapies|Intermediate Coverage Ratio ostherapies.com
- earnings and market ratios statistics:
OSTX - Net Profit|Expected Net Profit OS Therapies Incorporated|OSTX - Price to Earnings Ratio|Future Price to Earnings Multiple ostherapies.com|OSTX - PEG Multiple|EV/EBITDA Multiple OS Therapies|OSTX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months OS Therapies|OSTX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ostherapies.com|OSTX - Earnings growth in current year|Expected net earnings per share growth next year OS Therapies Incorporated
Fundamental company valuation:OS Therapies, Inc.
For OS Therapies Incorporated, which operates within a specific immuno-oncology drug development cycle, this metric serves as an indicator of operational efficiency excluding financial and tax expenses. By analyzing the EBITDA growth trajectory, an investor sees the current value of 0.00, which allows for an assessment of the business's intrinsic value based solely on clinical trial progress rather than external macroeconomic factors.
Competitor analysis for OS Therapies Incorporated
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Delcath Systems DCTH|Operating income before deduction of amortization Y-mAbs Therapeutics Inc (YMAB)|AURA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CADL (Candel Therapeutics)|ARAY (Accuray Incorporated) - Operating profit before deduction of amortization|SLS: Company profit before taxes, interest and amortization|ACTU (Actuate Therapeutics) - Operating profit EBITDA|CTOR: Income before deduction of interest, taxes and amortization|Operating profit EBITDA HURA|TARA - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|Income before deduction of interest, taxes and amortization WHWK|TScan - Operating profit EBITDA|CSBR - Operating profit EBITDA|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CVM (CEL-SCI)|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Artiva (ARTV) - Operating income before deduction of amortization|Operating profit EBITDA ANL|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Tx TPST|Operating income before deduction of amortization Xilio Therapeutics Inc (XLO)|RENB: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization MURA (Mural Oncology plc)|KAPA: Operating profit EBITDA|OKUR - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization CytoMed Therapeutics Ltd|Operating profit before amortization CRIS (Curis Corp)|Operating profit EBITDA APLM|Operating profit before deduction of amortization tharimmune.com THAR|Profit before payment of interest, taxes and amortization Advanced Biomed ADVB|Genprex Inc. (GNPX) - Profit before interest, taxes and amortization|CLDI - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization SBFM (sunshinebiopharma.com)|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization SLRX (salariuspharma.com)|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|Profit before interest, taxes and amortization AON AONC|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ELEV (Elevation Oncology)|Operating profit EBITDA iCAD Inc. ICAD|IKNA: Operating profit before deduction of amortization|Notable Labs Ltd - Company profit before taxes, interest and amortization|VIRX: Operating profit EBITDA|Profit before interest, taxes and amortization MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before amortization AAPGV (ascentage.com)
